Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study

Luigi E. Adinolfi, Salvatore Petta, Anna L. Fracanzani, Riccardo Nevola, Carmine Coppola, Vincenzo Narciso, Luca Rinaldi, Vincenza Calvaruso, Pia Clara Pafundi, Rosa Lombardi, Laura Staiano, Vito Di Marco, Antonio Solano, Aldo Marrone, Mariarosaria Saturnino, Francesca Rini, Barbara Guerrera, Graziano Troina, Mauro Giordano, Antonio CraxìFerdinando C. Sasso

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To assess the effect of hepatitis C virus (HCV) eradication on type 2 diabetes mellitus (T2DM) incidence. Methods: A prospective multicentre case–control study was performed, which included 2426 patients with HCV, 42% of whom had liver fibrosis stage F0-F2 and 58% of whom had liver fibrosis stage F3-F4. The study population consisted of a control group including 1099 untreated patients and 1327 cases treated with direct-acting antivirals (DAAs). T2DM incidence was assessed during a median (interquartile range) follow-up period of 30 (28–42) months. Risk factors for T2DM were assessed using a Cox regression model (relative risk [RR], hazard ratio [HR], Kaplan–Meier analysis). Insulin sensitivity was evaluated by homeostatic model assessment (HOMA) and changes by repeated-measures ANOVA. Factors independently associated with T2DM were assessed by multivariate analysis. Results: The absolute incidence of T2DM for controls and cases was 28 and 7/1000 person-years, respectively (P = 0.001). In cases compared to controls, HCV clearance reduced the RR and HR of T2DM by 81% and 75% to 93%, respectively (P = 0.001). It was calculated that, for every 15 patients who obtained HCV clearance, one case of T2DM was saved. HCV clearance was associated with significant reductions in HOMA-insulin resistance and HOMA-β-cell function and an increase in HOMA-insulin sensitivity, as assessed in 384 patients before and after HCV clearance. At multivariate analysis, HCV clearance emerged as independently associated with a reduced T2DM risk. Conclusion: The results showed that HCV clearance by DAA treatment probably reduces T2DM incidence by restoring the HCV-induced alteration of glucose homeostasis mechanisms.

Original languageEnglish
Pages (from-to)2408-2416
JournalDiabetes, Obesity and Metabolism
Volume22
Issue number12
DOIs
Publication statusPublished - 2020

Keywords

  • chronic hepatitis
  • cirrhosis
  • direct-acting antivirals
  • HCV
  • type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study'. Together they form a unique fingerprint.

Cite this